Biotechnology company United Therapeutics (NASDAQ: UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.
United Therapeutics beat analysts’ revenue expectations by 5.6% last quarter, reporting revenues of $794.4 million, up 17.2% year on year. It was a very strong quarter for the company, with a narrow beat of analysts’ EPS estimates.
Is United Therapeutics a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting United Therapeutics’s revenue to grow 12.3% year on year to $802.9 million, slowing from the 19.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $7.30 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. United Therapeutics has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3.9% on average.
With United Therapeutics being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. United Therapeutics is up 3.8% during the same time and is heading into earnings with an average analyst price target of $380.98 (compared to the current share price of $298.14).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
